Heart failure & cardiomyopathies
Effects of Tirzepatide in Obesity-Related Heart Failure with Preserved Ejection Fraction (HFpEF) by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial
Authors' conclusion
Despite these differences, tirzepatide resulted in consistent benefits across multiple domains of HF severity that did not differ by sex.
Study context
- Population
- Patients with NYHA class II–IV HFpEF and body mass index (BMI) ≥30 kg/m² (obesity-related HFpEF)393 women · 338 men
- Participants
- 731 patients
- Comparison
- Tirzepatide vs placebo, in women and men
- Tirzepatiden = 364
- Placebon = 367reference
- Primary endpoint
- Time to CV death or worsening HF; change in KCCQ-CSS
- Follow-up
- 52 weeks
Methodological detailssubgroup analysis by sex
- Subgroup analysis by sex
Primary result
As reported in the abstract
Primary outcomes by sex
- Women; worsening heart failure (HF) or CV death
- HR 0.66
- Men; worsening HF or CV death
- HR 0.61
- Women; Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS)
- placebo-corrected improvement 8.1 points
- Men; KCCQ-CSS
- placebo-corrected improvement 5.5 points
Secondary outcomes
| Outcome | Placebo-corrected improvement (m) |
|---|---|
| 6MWD by sex · 52 weeks — Tirzepatide vs Placebo · women | 18 |
| 6MWD by sex · 52 weeks — Tirzepatide vs Placebo · men | 15 |
- 6MWD by sex: interaction P = 0.76
Higher waist to height ratio (WHtR) and poorer kidney function · baseline
- Associated exclusively in women
- interaction P = 0.043
Weight loss on tirzepatide and KCCQ-CSS improvement
- More strongly associated in women than men
- interaction P = 0.0058
Original publication
Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. JACC Heart Fail. Published 7 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it